Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2016', provides in depth analysis on Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Overview 9
Therapeutics Development 10
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Stage of Development 10
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Therapy Area 11
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Indication 12
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Companies 16
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Universities/Institutes 19
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment 21
Assessment by Monotherapy/Combination Products 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development 28
Bayer AG 28
Boehringer Ingelheim GmbH 29
Ironwood Pharmaceuticals, Inc. 30
Mallinckrodt Plc 31
NicOx S.A. 32
SynZyme Technologies, LLC 33
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles 34
A-8R - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BAY sGCact - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BAY sGCstim - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BI-703704 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
hydroxyurea - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
IW-1701 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
IW-1973 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
IWP-953 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
naproxcinod - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
NCX-1021 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
NCX-250 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
NCX-422 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
NCX-429 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NCX-434 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
NCX-466 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NCX-470 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
NCX-667 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
nitric oxide - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
nitric oxide - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Q-201 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
riociguat - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecule to Inhibit Platelet Aggregation for Cardiovascular Disease - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Vacno - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
vericiguat - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Projects 69
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products 76
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Featured News & Press Releases 77
May 13, 2016: Bayer to Present Pulmonary Hypertension Data at American Thoracic Society 2016 International Conference 77
May 12, 2016: Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias 78
Mar 30, 2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IW-1973 at Upcoming Scientific Conferences 79
Mar 30, 2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IWP-953 at Upcoming Scientific Conferences 79
Feb 18, 2016: Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701 80
Nov 06, 2015: Latest Clinical Data of Vericiguat To Be Presented at Late-Breaking-Clinical-Trial Session at AHA 81
Nov 03, 2015: Ironwood Pharmaceuticals Initiates Clinical Study of Soluble Guanylate Cyclase Stimulator IW-1973 81
Nov 03, 2015: Ironwood Pharmaceuticals Initiates Clinical Study of Soluble Guanylate Cyclase Stimulator IW-1701 82
Oct 30, 2015: Mallinckrodt's INOmax Approved In Australia And Japan For Pulmonary Hypertension In Conjunction With Heart Surgery 82
Oct 22, 2015: Bayer to Present Pulmonary Arterial Hypertension Data at American College of Chest Physicians Annual Meeting 83
Oct 07, 2015: Bayer to Evaluate Riociguat in Children Suffering from Pulmonary Arterial Hypertension 84
Jul 22, 2015: Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973 84
Jun 23, 2015: Novoteris Announces $2.8 Million Award from Cystic Fibrosis Foundation Therapeutics to Support Development of Inhaled Nitric Oxide Antimicrobial Therapy 85
May 15, 2015: Bayer to Present Data on Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension at ATS 2015 International Conference 85
May 11, 2015: Promising preclinical data on NCX 667 for glaucoma presented at ARVO by Nicox 87
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89

List of Tables

Number of Products under Development for, H1 2016 10
Number of Products under Development by Therapy Area, H1 2016 11
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 20
Assessment by Monotherapy/Combination Products, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Pipeline by Bayer AG, H1 2016 28
Pipeline by Boehringer Ingelheim GmbH, H1 2016 29
Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 30
Pipeline by Mallinckrodt Plc, H1 2016 31
Pipeline by NicOx S.A., H1 2016 32
Pipeline by SynZyme Technologies, LLC, H1 2016 33
Dormant Projects, H1 2016 69
Dormant Projects (Contd..1), H1 2016 70
Dormant Projects (Contd..2), H1 2016 71
Dormant Projects (Contd..3), H1 2016 72
Dormant Projects (Contd..4), H1 2016 73
Dormant Projects (Contd..5), H1 2016 74
Dormant Projects (Contd..6), H1 2016 75
Discontinued Products, H1 2016 76